Cevec, Paragon in CAP technology license agreement

Under the license, Paragon will use Cevec’s CAP and CAP-T cell expression system to perform process development and develop stable cell lines for the contract manufacturing of recombinant proteins and antibodies.

Cevec CEO Wolfgang Kintzel said, "Since they provide preclinical research and development services and protein production for many of the large pharmaceutical companies, we believe that our collaboration will inevitably benefit the research community at-large."

Paragon CEO Marco Chacon said everyone needs an edge to meet the outsourcing challenges of the company’s clients.

"This valuable tool from CEVEC will assist us in offering clients a fully optimized human expression system that will express proteins with superior yields and in a shorter time frame than traditional methods," Chacon added.